Is immunosuppressive therapy an effective treatment for COVID-19? – literature review
DOI:
https://doi.org/10.12775/JEHS.2023.29.01.005Keywords
COVID-19, SARS-CoV-2, immunosuppressive therapy, tocilizumab, sarilumab, siltuximab, baricitinibAbstract
Introduction: The disease caused by SARS-CoV-2 is associated with a dysregulated immune response and a generalized inflammatory response. Therefore, during the search for effective therapy, attention was paid to drugs affecting and stabilizing such a response - tocilizumab, sarilumab, siltuximab, anakinra, baricitinib.
Purpose of the work: Evaluation of the impact of immunosuppressant therapy on the course of the disease caused by the SARS-CoV-2 virus.
Material and methods: The work was based on a review of available medical publications about immunosuppressive therapy for COVID-19 treatment. The literature in the PubMed and Google Scholar databases was searched based on the following keywords: tocilizumab, sarilumab, siltuximab, baricitinib, COVID-19, SARS-CoV-2, immunosuppressive therapy.
Conclusion: Based on the analysis of the literature, the most effective therapeutic option seems to be tocilizumab. Promising alternatives may be sarilumab and siltuximab as they have the same target point of action. However, it is necessary to conduct further tests on their operation. The use of baricitinib may be useful, but probably only in certain circumstances. Anakinra proved to be much less effective. It should therefore be used with great caution.
References
Peng J, Fu M, Mei H, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: a systematic review and meta‐analysis. Rev Med Virol. 2022;32(3):e2295
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, Jenkins G. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12. PMID: 33579777; PMCID: PMC7886668
Yu SY, Koh DH, Choi M, Ryoo S, Huh K, Yeom JS, Yoon YK. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Dec;11(1):1154-1165. doi: 10.1080/22221751.2022.2059405. PMID: 35343397; PMCID: PMC9037226.
RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. PMID: 35908569; PMCID: PMC9333998.
Wei Q, Lin H, Wei RG, Chen N, He F, Zou DH, Wei JR. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty. 2021 May 18;10(1):71. doi: 10.1186/s40249-021-00857-w. PMID: 34001244; PMCID: PMC8128625.
Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Trans Med. 2020;18:406. https://doi.org/10.1186/s12967-020-02571-x.
Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, et al. Efects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2021;27(2):238–43. https://doi.org/10.1016/j.cmi.2020.09.021.
Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: a retrospective cohort study. EclinicalMedicine. 2020. https://doi.org/10.1016/j.eclinm.2020.100418.
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efcacy of tocilizumab in patients hospitalized with Covid-19. NEngl J Med. 2020;383:2333–44. https://doi.org/10.1056/NEJMoa2028836
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2030340.
Avni T, Leibovici L, Cohen I, et al. Tocilizumab in the treatment of COVID-19-a meta-analysis. QJM. 2021 Nov 5;114(8):577–586.
Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19: a systematic review and metaanalysis. J Med Virol. 2021;93(3):1620–1630.
Belletti A, Campochiaro C, Marmiere M, et al. Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. Ann Intensive Care. 2021 Oct 26;11(1):152.
Malgie J, Schoones JW, Pijls BG. Decreased mortality in coronavirus disease 2019 patients treated with 1164 S.-Y. Yu et al. tocilizumab: a rapid systematic review and metaanalysis of observational studies. Clin Infect Dis. 2021 Jun 1;72(11):e742–e749.
Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021 Aug 10;326 (6):499–518. 16. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020 Nov;30(6):1-9. doi: 10.1002/rmv.2141. Epub 2020 Aug 26. PMID: 32845568; PMCID: PMC7460877.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330. PMID: 34228774; PMCID: PMC8261689.
Albuquerque AM, Eckert I, Tramujas L, Butler-Laporte G, McDonald EG, Brophy JM, Lee TC. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clin Microbiol Infect. 2023 Jan;29(1):13-21. doi: 10.1016/j.cmi.2022.07.008. Epub 2022 Jul 19. PMID: 35863630; PMCID: PMC9293401.
Lim PC, Wong KL, Rajah R, Chong MF, Chow TS, Subramaniam S, Lee CY. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. Daru. 2022 Jun;30(1):211-228. doi: 10.1007/s40199-021-00430-8. Epub 2022 Jan 27. PMID: 35084705; PMCID: PMC8792140.
Mahroum N, Watad A, Bridgewood C, Mansour M, Nasr A, Hussein A, Khamisy-Farah R, Farah R, Gendelman O, Lidar M, Shoenfeld Y, Amital H, Kong JD, Wu J, Bragazzi NL, McGonagle D. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. Int J Environ Res Public Health. 2021 Aug 30;18(17):9149. doi: 10.3390/ijerph18179149. PMID: 34501738; PMCID: PMC8431489.
Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. J Immunother Cancer. 2022 Apr;10(4):e002838. doi: 10.1136/jitc-2021-002838. PMID: 35459733; PMCID: PMC9035837.
Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021 Sep;35(9):2616-2620. doi: 10.1038/s41375-021-01266-6. Epub 2021 May 14. PMID: 33990684; PMCID: PMC8119232.
Manoharan S, Ying LY. Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. Respir Med. 2022 Oct;202:106986. doi: 10.1016/j.rmed.2022.106986. Epub 2022 Sep 16. PMID: 36150282; PMCID: PMC9477792.
Tahsini Tekantapeh S, Ghojazadeh M, Ghamari AA, Mohammadi A, Soleimanpour H. Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis. Expert Rev Respir Med. 2022 Oct;16(10):1109-1132. doi: 10.1080/17476348.2022.2114899. Epub 2022 Sep 8. PMID: 35981253.
Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022 Mar;20(3):425-434. doi: 10.1080/14787210.2021.1982695. Epub 2021 Sep 29. PMID: 34538216; PMCID: PMC8500309.
Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct;99:108027. doi: 10.1016/j.intimp.2021.108027. Epub 2021 Jul 31. PMID: 34343937; PMCID: PMC8324418.
Lin Z, Niu J, Xu Y, Qin L, Ding J, Zhou L. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2022 Apr;94(4):1523-1534. doi: 10.1002/jmv.27482. Epub 2021 Dec 13. PMID: 34846766; PMCID: PMC9015594.
Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov;40(11):4671-4674. doi: 10.1007/s10067-021-05884-4. Epub 2021 Aug 24. PMID: 34431004; PMCID: PMC8384394.
Peng J, Fu M, Mei H, Zheng H, Liang G, She X, Wang Q, Liu W. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2022 May;32(3):e2295. doi: 10.1002/rmv.2295. Epub 2021 Sep 24. PMID: 34558756; PMCID: PMC8646369.
Dahms K, Mikolajewska A, Ansems K, Metzendorf MI, Benstoem C, Stegemann M. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. Eur J Med Res. 2023 Feb 25;28(1):100. doi: 10.1186/s40001-023-01072-z. PMID: 36841793; PMCID: PMC9959952.
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, Jenkins G. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12. PMID: 33579777; PMCID: PMC7886668.
Shang W, Zhang Y, Wang G, Han D. Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Rev Med Virol. 2023 Mar;33(2):e2418. doi: 10.1002/rmv.2418. Epub 2023 Jan 4. PMID: 36600551.
Naveed Z, Sarwar M, Ali Z, Saeed D, Choudhry K, Sarfraz A, Sarfraz Z, Felix M, Cherrez-Ojeda I. Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis. J Clin Lab Anal. 2022 Jun;36(6):e24434. doi: 10.1002/jcla.24434. Epub 2022 Apr 18. PMID: 35435272; PMCID: PMC9110982.
Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, Likhvantsev VV, Zangrillo A, Dagna L, Monti G. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med. 2021 Apr;86:34-40. doi: 10.1016/j.ejim.2021.01.016. Epub 2021 Feb 5. PMID: 33581979; PMCID: PMC7862887.
Malık H, Bınt Abdul Jabbar H, Latıf F, Sarfraz A, Sarfraz Z, Sarfraz M. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis. Turk J Med Sci. 2022 Jun;52(3):547-553. doi: 10.55730/1300-0144.5345. Epub 2022 Jun 16. PMID: 36326309.
Barkas F, Filippas-Ntekouan S, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 1;60(12):5527-5537. doi: 10.1093/rheumatology/keab447. PMID: 33999135; PMCID: PMC8194671.
European Medicines Agency. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/kiner et-epar-product-information_en.pdf. Accessed 17 Mar 2022.
van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care Med. 2020;24:445.
European Medicines Agency. Assessment Report Kineret. https://www. ema.europa.eu/en/documents/variation-report/kineret-h-c-000363-ii- 0086-epar-assessment-report-variation_en.pdf. Accessed 7 Apr 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Barbara Ostrowska, Kacper Kołodziejczyk, Justyna Branewska, Izabela Hop, Mikołaj Matysek, Anna Olszanicka, Jan Imioło, Anna Maciąg, Rafał Niemiec, Adam Galas
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 361
Number of citations: 0